Lunai Bioworks Inc. (LNAI) · Oct 9, 2026 · Other events
Trading suspension request — Nasdaq has not decided; the request itself does not halt trading
Lunai Bioworks filed a trading suspension request with Nasdaq, escalating its short-selling lawsuit while leaving any halt decision unresolved.
Lunai is an AI-enabled biotechnology company building drug-discovery and biodefense capabilities, including chemical-threat assessment through its BioSymetrics platform. This filing shifts the near-term story from biotech execution to market integrity. Lunai formally asked Nasdaq to immediately suspend trading while regulators review records tied to its pending lawsuit against Seven Points Capital and other defendants. 〔0〕
The escalation is new, but the underlying dispute is not. The company says court-ordered discovery uncovered substantial short selling, locate deficiencies and concentrated failures to deliver, but those are still allegations in pending litigation rather than established findings. 〔1〕 That makes this more consequential than a routine litigation update, while limiting how much certainty investors can attach to the claims.
The immediate business effect is unresolved disruption, not an actual trading halt. Nasdaq had not ruled as of the filing, and the company cannot predict whether or when it will respond. 〔2〕 The filing therefore adds regulatory and market-structure uncertainty around the company, but does not yet change its biotech programs, funding, or operating plans.
Bottom line: This is a meaningful legal and trading-market escalation, but not a confirmed suspension or regulatory finding. It raises the visibility of Lunai’s short-selling dispute while leaving the central allegations and Nasdaq’s response unresolved—so the read is mixed rather than cleanly positive or negative for the business story.
Nasdaq response on suspension or other protective action
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!